Stroke Update 2011: New Antithrombotics / 대한뇌졸중학회지
Korean Journal of Stroke
;
: 62-66, 2012.
Artigo
em Coreano
| WPRIM
| ID: wpr-14871
ABSTRACT
Several new antithrombotic drugs have been developed and approved to use in clinical practice recently. Dabigatran, a direct thrombin inhibitor, and rivaroxaban, a factor Xa inhibitor, have been approved in many countries including Korea to prevent stroke in patient with atrial fibrillation. Apixaban, another factor Xa inhibitor, showed good results in clinical trial and is waiting for approval for clinical use. New antiplatelet agent, terutroban, selective thromboxane A2 receptor inhibitor, failed to prove the efficacy over the aspirin in secondary stroke prevention. Vorapaxar, a new antiplatelet agent that inhibits thrombin through PAR-1 antagonism, showed a high incidence of intracranial hemorrhage in patient with a history of stroke.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Propionatos
/
Pirazóis
/
Piridinas
/
Piridonas
/
Fibrilação Atrial
/
Tiofenos
/
Benzimidazóis
/
Trombina
/
Fator Xa
/
Aspirina
Tipo de estudo:
Estudo de incidência
/
Estudo prognóstico
Limite:
Humanos
País/Região como assunto:
Ásia
Idioma:
Coreano
Revista:
Korean Journal of Stroke
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS